clinical trial · NCT06282575
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Biliary Tract CancerZanidatamabCisplatinGemcitabinePembrolizumabDurvalumab
brief summary
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
started
Jul 19, 2024
primary completion
Dec 1, 2028
completion
Apr 1, 2030
last updated
May 11, 2026
official title
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol